[go: up one dir, main page]

AR030278A1 - Peptido modulador del receptor de trombopoyetina - Google Patents

Peptido modulador del receptor de trombopoyetina

Info

Publication number
AR030278A1
AR030278A1 ARP010101924A ARP010101924A AR030278A1 AR 030278 A1 AR030278 A1 AR 030278A1 AR P010101924 A ARP010101924 A AR P010101924A AR P010101924 A ARP010101924 A AR P010101924A AR 030278 A1 AR030278 A1 AR 030278A1
Authority
AR
Argentina
Prior art keywords
tpo
nucleotide sequences
methods
oligopeptide
oligopeptides
Prior art date
Application number
ARP010101924A
Other languages
English (en)
Inventor
Olsson Lennart Dr
Naranda Tatjana Dr
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of AR030278A1 publication Critical patent/AR030278A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describe un oligopéptido que presenta la actividad biologica de un compuesto modulador del receptor de trombopoyetina (TPO), que comprende 15 a 18 aminoácidos con la siguiente formula general: X1 G T L E L X2 P X3 S R Y R L Q L X4, donde X1 es A R G o falta, X2 es R o A, X3 es R o A y X4 es R A R o falta, o un equivalente biologico del mismo. También se describen las secuencias de nucleotidos que codifican a dicho oligopéptido, los vectores que comprenden las secuencias de nucleotidos, las células huésped que comprenden los vectores, los anticuerpos que son reactivos con los oligopéptidos, las composiciones farmacéuticas y de diagnostico que comprenden a los oligopéptidos, a las secuencias de nucleotidos, a los anticuerpos y/o células huésped, así como los métodos para modificar genéticamente una célula, los métodos para modular la actividad de un receptor TPO (TPO-R) y los métodos para examinar otros compuestos moduladores del receptor TPO. Con el oligopéptido aislado y purificado que se describe más arriba, el cual presenta la actividad biologica de un modulador de la TPO, se resuelve el problema de proveer un compuesto efectivo y util para el diagnostico y el tratamiento de los trastornos hematologicos, tal como la trombocitopenia idiopática e inducida, en particular, la trombocitopenia inducida por quimioterapia, alergia e irradiacion, que al mismo tiempo sea estable y no toxico.
ARP010101924A 2000-04-25 2001-04-25 Peptido modulador del receptor de trombopoyetina AR030278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00108075A EP1149906A1 (en) 2000-04-25 2000-04-25 Thrombopoietin receptor modulating peptide

Publications (1)

Publication Number Publication Date
AR030278A1 true AR030278A1 (es) 2003-08-20

Family

ID=8168467

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101924A AR030278A1 (es) 2000-04-25 2001-04-25 Peptido modulador del receptor de trombopoyetina

Country Status (24)

Country Link
US (1) US20030181659A1 (es)
EP (2) EP1149906A1 (es)
JP (1) JP2003530867A (es)
KR (1) KR20030009450A (es)
CN (1) CN1426467A (es)
AR (1) AR030278A1 (es)
AU (2) AU2001267366B9 (es)
BG (1) BG107214A (es)
BR (1) BR0110383A (es)
CA (1) CA2407167A1 (es)
CZ (1) CZ20023517A3 (es)
EA (1) EA006423B1 (es)
EE (1) EE200200610A (es)
GE (1) GEP20063763B (es)
HU (1) HUP0300559A3 (es)
IL (1) IL152204A0 (es)
IS (1) IS6582A (es)
MX (1) MXPA02010458A (es)
NO (1) NO20025114L (es)
PL (1) PL358304A1 (es)
SK (1) SK15262002A3 (es)
WO (1) WO2001080873A2 (es)
YU (1) YU79202A (es)
ZA (1) ZA200208662B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039476A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
CA2499625A1 (en) * 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
PL377477A1 (pl) 2002-12-11 2006-02-06 Ferrosan A/S Materiały na bazie żelatyny jako waciki
CN1849141A (zh) * 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
JP2005187435A (ja) * 2003-12-26 2005-07-14 Otsuka Chemical Co Ltd 血小板産生促進組成物
US7923031B2 (en) 2004-01-30 2011-04-12 Ferrosan Medical Devices A/S Haemostatic sprays and compositions
CN101001649B (zh) 2004-07-09 2011-08-31 弗罗桑医疗设备公司 包括透明质酸的止血组合物及其制备方法
US20090004673A1 (en) * 2006-01-31 2009-01-01 Mitsubishi Kagaku Iatron, Inc. Method for Determining Condition of Disseminated Intravascular Coagulation
WO2009109194A2 (en) 2008-02-29 2009-09-11 Ferrosan A/S Device for promotion of hemostasis and/or wound healing
SG195007A1 (en) * 2011-05-13 2013-12-30 Univ Tokyo Polynucleated megakaryocytic cell and method for manufacturing platelets
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
EP3237041B1 (en) 2014-12-24 2020-01-29 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
AU2019266529B2 (en) 2018-05-09 2024-05-23 Ethicon Inc. Method for preparing a haemostatic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1064015A2 (en) * 1998-02-24 2001-01-03 Receptron, Inc. Receptor derived peptides as modulators of receptor activity

Also Published As

Publication number Publication date
AU2001267366B2 (en) 2005-06-30
HUP0300559A3 (en) 2005-09-28
SK15262002A3 (sk) 2003-05-02
GEP20063763B (en) 2006-03-10
WO2001080873A3 (en) 2002-01-31
BG107214A (bg) 2003-11-28
IS6582A (is) 2002-10-14
WO2001080873A2 (en) 2001-11-01
IL152204A0 (en) 2003-05-29
EA006423B1 (ru) 2005-12-29
EP1278849A2 (en) 2003-01-29
MXPA02010458A (es) 2003-06-06
JP2003530867A (ja) 2003-10-21
NO20025114L (no) 2002-12-18
CN1426467A (zh) 2003-06-25
PL358304A1 (en) 2004-08-09
CA2407167A1 (en) 2001-11-01
KR20030009450A (ko) 2003-01-29
NO20025114D0 (no) 2002-10-24
YU79202A (sh) 2006-01-16
AU2001267366B9 (en) 2005-07-14
CZ20023517A3 (cs) 2003-10-15
EA200201138A1 (ru) 2003-06-26
AU6736601A (en) 2001-11-07
EP1149906A1 (en) 2001-10-31
HUP0300559A2 (hu) 2003-06-28
ZA200208662B (en) 2003-10-27
EE200200610A (et) 2004-08-16
US20030181659A1 (en) 2003-09-25
BR0110383A (pt) 2003-01-21

Similar Documents

Publication Publication Date Title
AR030278A1 (es) Peptido modulador del receptor de trombopoyetina
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
AR048744A1 (es) Polipeptidos cristalinos y polinucleotidos de bacillus thuringiensis y composiciones con los mismos
EP2267023A3 (en) KDR peptides and vaccines comprising the same
DE69605544D1 (de) Peptidverbindungen mit wachstumsfaktorähnlicher aktivität
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
DK0750506T3 (da) Bredspektrede, antimikrobielle forbindelser og fremgangsmåder til anvendelse af disse
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
CO5590973A2 (es) Acido nucleico de adenovirus de simio y secuiencias de aminoacidos, vectores que contienen los mismos y metodos de uso
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
EA200802018A1 (ru) Новые гены, кодирующие инсектицидные белки
DE60329201D1 (de) Substituierte wt1-peptide
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
RU2009147217A (ru) Новые противоопухолевые соединения
BR9810478A (pt) Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização
AR064252A1 (es) Plantas que presentan caracteristicas acrecentadas relacionadas con el rendimiento y un metodo para producir las mismas
ES2133295T3 (es) Peptidos ciclicos y su uso.
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
ATE242202T1 (de) Peptide
DE69618574D1 (de) Vom desmingen abstammende amplifizierungssequenzen, vektoren, die diese enthalten und anwendungen derselben zur herstellung von proteinen
AR039021A1 (es) Gen humano de la proteasa desubiquitinante del cromosoma 7 y su ortologo murino
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
RU2004103078A (ru) Молекулы иммунного связывания, ингибирующие синцитиальное слияние клеток трофобласта
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40

Legal Events

Date Code Title Description
FB Suspension of granting procedure